B-hPD-1/hTIGIT Mice

Basic Information

Strain Name
C57BL/6-Pdcd1tm1(PDCD1) Tigittm1(TIGIT)/Bcgen
Stock Number
120523
Common Name
B-hPD-1/hTIGIT mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
PD-1(Programmed death-1); TIGIT (T-cell immunoreceptor with Ig and ITIM domains)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Targeting Strategy

Details

Phenotype

mRNA Expression Analysis

RT-PCR analysis of the B-hPD-1/hTIGIT humanized mice.

The splenocytes of the B-hPD-1/hTIGIT homozygous mice showed expression of human PD-1 and TIGIT mRNA but not mouse PD-1 and TIGIT mRNA.

Protein Expression Analysis

Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/hTIGIT mice were analyzed by flow cytometry. Mouse TIGIT+ and mouse PD-1+ T cells were detectable in the WT C57BL/6 mice, while human TIGIT+ and PD-1+ T cells were detectable in the homozygous B-hPD-1/hTIGIT mice.

Application

Combination therapy of TIGIT (Tiragolumab Analog) mAb and PD-1 mAb

B-hPD-1hTIGIT-PD-1

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hPD-1/hTIGIT mice. Mice were grouped when the tumor size was approximately 150±50 mm3 (n=6). Anti-hTIGIT antibody and the anti-hPD-1 antibody Keytruda shows obviously inhibitory effects respectively. Combination of anti-hTIGIT antibody and the anti-hPD-1 antibody Keytruda shows better inhibitory effects than single treatment, suggesting that B-hPD-1 /hTIGIT mouse is a powerful tool for in vivo evaluating combination therapy efficacy of hPD-1 antibodies and hTIGIT antibodies . (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

  1. Journal of Biomedical Science (2017) 24:26 doi: 10.1186/s12929-017-
    0329-9
  2. J Clin Invest. 2015;125(5):2046–2058. doi:10.1172/JCI80445
  3. Cancer Cell (2014), http://dx.doi.org/10.1016/j.ccell.2014.10.018
Back to top